State of New Jersey Common Pension Fund D Purchases 5,427 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

State of New Jersey Common Pension Fund D raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 13.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,901 shares of the company's stock after purchasing an additional 5,427 shares during the period. State of New Jersey Common Pension Fund D's holdings in Vaxcyte were worth $3,676,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of PCVX. Creative Planning grew its stake in shares of Vaxcyte by 37.6% during the third quarter. Creative Planning now owns 37,525 shares of the company's stock worth $4,288,000 after purchasing an additional 10,245 shares during the period. Blue Trust Inc. boosted its holdings in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after buying an additional 93 shares during the last quarter. Raymond James & Associates grew its position in shares of Vaxcyte by 17.0% during the 3rd quarter. Raymond James & Associates now owns 81,235 shares of the company's stock worth $9,283,000 after buying an additional 11,798 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Vaxcyte by 1.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 347,474 shares of the company's stock valued at $39,706,000 after acquiring an additional 3,922 shares during the last quarter. Finally, Signaturefd LLC raised its position in shares of Vaxcyte by 51.9% in the 3rd quarter. Signaturefd LLC now owns 1,048 shares of the company's stock valued at $120,000 after acquiring an additional 358 shares during the period. Institutional investors own 96.78% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PCVX. Needham & Company LLC restated a "buy" rating and set a $14.00 price objective on shares of Vaxcyte in a report on Tuesday, February 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $127.71.

Vaxcyte Stock Down 1.9 %

Shares of NASDAQ:PCVX traded down $1.57 during midday trading on Friday, reaching $80.90. 601,343 shares of the company were exchanged, compared to its average volume of 1,065,726. The stock has a fifty day simple moving average of $85.77 and a two-hundred day simple moving average of $94.57. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06. The firm has a market cap of $10.08 billion, a PE ratio of -17.54 and a beta of 0.98.

Insider Buying and Selling

In other news, SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total value of $457,450.00. Following the completion of the sale, the senior vice president now owns 28,697 shares of the company's stock, valued at approximately $2,625,488.53. This represents a 14.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Teri Loxam sold 6,250 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 76,616 shares of company stock worth $6,766,481. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.